Applied DNA Sciences Inc. (APDN)
| Bid | 4.65 |
| Market Cap | 2.58M |
| Revenue (ttm) | 3.79M |
| Net Income (ttm) | -31.28M |
| EPS (ttm) | 3370.12 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.06 |
| Analyst | Buy |
| Ask | 5.29 |
| Volume | 108,419 |
| Avg. Volume (20D) | 128,055 |
| Open | 4.70 |
| Previous Close | 4.67 |
| Day's Range | 4.41 - 5.02 |
| 52-Week Range | 4.35 - 2655.00 |
| Beta | 0.05 |
About APDN
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for APDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · accessnewswire.com
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec...
1 month ago · accessnewswire.com
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results- Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June ...
2 months ago · accessnewswire.com
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price RequirementSTONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a...
